IP Library Granted Patent US 10,960,025
Granted Patent B2
US 10,960,025 · App. 16/811,900 · Granted Mar 30, 2021

Mesenchymal stem cells and uses therefor

Inventors: Sudeepta Aggarwal (North Potomac, MD); Mark F. Pittenger (Severna Park, MD); Timothy Varney (Baltimore, MD)
Assignee: Mesoblast International Sárl
A61K35/28A61K38/2026A61K38/2066A61K45/06A61P11/00C12N5/0662C12N5/0663C12N5/0664C12N5/0665C12N5/0666C12N5/0667C12N5/0668A61K2035/124Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,960,025
App. No.
16/811,900
Granted
Mar 30, 2021
Kind
B2
Abstract

Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.

Claims (14)

1. A method of treating inflammatory bowel disease in a patient, the method comprising administering to the patient a suspension of isolated, cultured, genetically unmanipulated mesenchymal stem cells, in an amount effective to limit the inflammation in the gut and treat the inflammatory bowel disease.

2. The method of claim 1 , wherein the mesenchymal stem cells are allogeneic.

3. The method of claim 1 , wherein the mesenchymal stem cells are autologous.

4. The method of claim 1 , wherein the suspension further comprises an acceptable pharmaceutical carrier.

5. The method of claim 1 , wherein the suspension is administered in an amount of from about 1×10 5 cells/kg to about 1×10 7 cells/kg.

6. The method of claim 1 , wherein the suspension is administered in an amount of from about 1×10 6 cells/kg to about 5×10 6 cells/kg.

7. The method of claim 1 , wherein the cultured, genetically unmanipulated mesenchymal stem cells are isolated from marrow.

8. The method of claim 7 , wherein the marrow is iliac crest marrow.

9. The method of claim 1 , wherein the mesenchymal stem cells increase secretion of interleukin-10.

10. The method of claim 1 , wherein the mesenchymal stem cells increase generation of regulatory T cells.

11. The method of claim 1 , wherein the patient is human and the mesenchymal stem cells are human.

12. The method of claim 2 , wherein the patient is human and the mesenchymal stem cells are human.

13. The method of claim 3 , wherein the patient is human and the mesenchymal stem cells are human.

14. The method of claim 1 , wherein the mesenchymal stem cells were isolated from blood, skin, cord blood, muscle, fat, bone, or perichondrium.

Assignments (4)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jan 2, 2026
From: OAKTREE FUND ADMINISTRATION, LLC, AS AGENT
To: MESOBLAST LIMITED; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 074174/0183 →
SECURITY INTEREST Recorded Dec 10, 2021
From: MESOBLAST LIMITED ACN 109 431 870; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 058957/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2020
From: AGGARWAL, SUDEEPTA; PITTENGER, MARK F.; VARNEY, TIMOTHY
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 052357/0939 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2020
From: OSIRIS THERAPEUTICS, INC.
To: MESOBLAST INTERNATIONAL SARL
Reel/Frame 052358/0194 →
Cited By (2)
US 12,697,355 US 12,702,683